{
    "clinical_study": {
        "@rank": "154540", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ZGN-440 sterile diluent"
            }, 
            {
                "arm_group_label": "0.3 mg Beloranib", 
                "arm_group_type": "Experimental", 
                "description": "0.3 mg ZGN-440 for injectable suspension"
            }, 
            {
                "arm_group_label": "0.6 mg Beloranib", 
                "arm_group_type": "Experimental", 
                "description": "0.6 mg ZGN-440 for injectable suspension"
            }, 
            {
                "arm_group_label": "1.2 mg Beloranib", 
                "arm_group_type": "Experimental", 
                "description": "1.2 mg ZGN-440 for injectable suspension"
            }, 
            {
                "arm_group_label": "2.4 mg Beloranib", 
                "arm_group_type": "Experimental", 
                "description": "2.4 mg ZGN-440 for injectable suspension"
            }, 
            {
                "arm_group_label": "3.2 mg Beloranib", 
                "arm_group_type": "Experimental", 
                "description": "3.2 mg ZGN-440 for injectable suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for\n      certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly\n      subcutaneous injections for 12 weeks."
        }, 
        "brief_title": "An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Weight Loss"
            ]
        }, 
        "detailed_description": {
            "textblock": "This protocol is designed to test the safety and efficacy of a drug called beloranib\n      (ZGN-440 for injectable suspension).  It is to be tested for its ability to reduce weight in\n      obese subjects.  The study will provide information on how much ZGN-440 gets into the blood,\n      how long it stays in the body, and how it affects other biological markers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Obese volunteers weighing \u2265 50 kg\n\n          -  BMI \u2265 30 and \u2264 50 kg/m2\n\n          -  Stable body weight during the past 2 months\n\n          -  Type 2 diabetes mellitus is allowed\n\n        Exclusion Criteria:\n\n          -  Use of weight loss agents in the past month\n\n          -  Current, clinically significant eating disorder\n\n          -  Type 1 diabetes mellitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666691", 
            "org_study_id": "ZAF-201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.3 mg Beloranib", 
                    "0.6 mg Beloranib", 
                    "1.2 mg Beloranib", 
                    "2.4 mg Beloranib", 
                    "3.2 mg Beloranib"
                ], 
                "description": "Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.", 
                "intervention_name": "Beloranib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ZGN-440 for injectable suspension", 
                    "ZGN-440", 
                    "ZGN-433", 
                    "Beloranib"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "ZGN-440 sterile diluent"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obese", 
            "Obesity", 
            "Overweight", 
            "Weight loss", 
            "Weight reduction", 
            "Beloranib"
        ], 
        "lastchanged_date": "May 21, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "Q-Pharm Clinics, Royal Brisbane and Women's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "CMAX"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }, 
                    "name": "Linear Clinical Research Ltd"
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "6", 
        "official_title": "Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks", 
        "overall_official": {
            "affiliation": "Q-Pharm Clinics, Royal Brisbane and Women's Hospital", 
            "last_name": "J K Marjason, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Australia: Human Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Safety and tolerability of beloranib will be assessed by comparing frequency and severity of adverse events as well as changes in physical examinations, ECGs, vital signs and laboratory evaluations. Other safety oriented questionnaires and parameters (e.g. sleep quality, hemodynamic parameters) will be measured and evaluated.", 
                "measure": "Safety and tolerability of beloranib (ZGN-440 for injectable suspension) administered subcutaneously for 12 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks"
            }, 
            {
                "description": "Change from baseline in body weight and body composition (bioimpedance assessments), and scores of hunger/appetite over the dosing period will be evaluated to document beloranib's effect on obesity. Biomarkers of lipid metabolism will be measured to assess possible mechanisms of loss of body fat, as well as endocrinologic or anti-inflammatory markers.", 
                "measure": "Weight loss and responses in metabolic biomarkers over a dose range of ZGN-440", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666691"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The plasma PK of beloranib and selected metabolites may be assessed following dose administration to compare systemic exposure and PK parameters over the range of doses.  PK parameters include Cmax, Tmax, AUC24hour, AUC\u221e, volume of distribution, total clearance, terminal elimination constant, and half-life.  Mean residence time may also be reported.", 
                "measure": "Pharmacodynamics over a dose range of beloranib", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Compare the plasma pharmacokinetic profile of beloranib administered subcutaneously with the profiles obtained previously using an alternative formulation administered subcutaneously and with ZGN-433 (beloranib hemioxalate) administered intravenously", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Bioavailability will be estimated from the SC PK parameters compared to the profile from comparable doses in earlier IV administration studies.", 
                "measure": "Apparent bioavailability over a dose range of beloranib", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Zafgen, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zafgen, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}